Michael J Twiner1, Alexander L Marinica2, Kenneth Kuper3, Allen Goodman4, James J Mahn5, Michael J Burla1, Aaron M Brody1, Justin A Carroll5, Robina Josiah Willock6, John M Flack7,8, Samar A Nasser9, Phillip D Levy8. 1. Department of Emergency Medicine, Wayne State University, Detroit, MI. 2. Department Surgery, Sinai Grace Hospital, Detroit, MI. 3. Department of Emergency Medicine, St. John Hospital, Detroit, MI. 4. Department of Economics, Wayne State University, Detroit, MI. 5. School of Medicine, Wayne State University, Detroit, MI. 6. Community Health & Preventive Medicine, Morehouse School of Medicine, Atlanta, GA. 7. Division of Transitional Research and Clinical Epidemiology and Department of Medicine, Wayne State University, Detroit, MI. 8. Cardiovascular Research Institute, Wayne State University, Detroit, MI. 9. College of Education, Health, and Human Services, University of Michigan-Dearborn, Dearborn, MI.
Abstract
OBJECTIVES: Poorly controlled hypertension (HTN) is extremely prevalent and, if left unchecked, subclinical hypertensive heart disease (SHHD) may ensue leading to conditions such as heart failure. To address this, we designed a multidisciplinary program to detect and treat SHHD in a high-risk, predominantly African American community. The primary objective of this study was to determine the cost-effectiveness of our program. METHODS: Study costs associated with identifying and treating patients with SHHD were calculated and a sensitivity analysis was performed comparing the effect of four parameters on cost estimates. These included prevalence of disease, effectiveness of treatment (regression of SHHD, reversal of left ventricular hypertrophy [LVH], or blood pressure [BP] control as separate measures), echocardiogram costs, and participant time/travel costs. The parent study for this analysis was a single-center, randomized controlled trial comparing cardiac effects of standard and intense (<120/80 mm Hg) BP goals at 1 year in patients with uncontrolled HTN and SHHD. A total of 149 patients (94% African American) were enrolled, 133 (89%) had SHHD, 123 (93%) of whom were randomized, with 88 (72%) completing the study. Patients were clinically evaluated and medically managed over the course of 1 year with repeated echocardiograms. Costs of these interventions were analyzed and, following standard practices, a cost per quality-adjusted life-year (QALY) less than $50,000 was defined as cost-effective. RESULTS:Total costs estimates for the program ranged from $117,044 to $119,319. Cost per QALY was dependent on SHHD prevalence and the measure of effectiveness but not input costs. Cost-effectiveness (cost per QALY less than $50,000) was achieved when SHHD prevalence exceeded 11.1% for regression of SHHD, 4.7% for reversal of LVH, and 2.9% for achievement of BP control. CONCLUSIONS: In this cohort of predominantly African American patients with uncontrolled HTN, SHHD prevalence was high and screening with treatment was cost-effective across a range of assumptions. These data suggest that multidisciplinary programs such as this can be a cost-effective mechanism to mitigate the cardiovascular consequences of HTN in emergency department patients with uncontrolled BP.
RCT Entities:
OBJECTIVES: Poorly controlled hypertension (HTN) is extremely prevalent and, if left unchecked, subclinical hypertensive heart disease (SHHD) may ensue leading to conditions such as heart failure. To address this, we designed a multidisciplinary program to detect and treat SHHD in a high-risk, predominantly African American community. The primary objective of this study was to determine the cost-effectiveness of our program. METHODS: Study costs associated with identifying and treating patients with SHHD were calculated and a sensitivity analysis was performed comparing the effect of four parameters on cost estimates. These included prevalence of disease, effectiveness of treatment (regression of SHHD, reversal of left ventricular hypertrophy [LVH], or blood pressure [BP] control as separate measures), echocardiogram costs, and participant time/travel costs. The parent study for this analysis was a single-center, randomized controlled trial comparing cardiac effects of standard and intense (<120/80 mm Hg) BP goals at 1 year in patients with uncontrolled HTN and SHHD. A total of 149 patients (94% African American) were enrolled, 133 (89%) had SHHD, 123 (93%) of whom were randomized, with 88 (72%) completing the study. Patients were clinically evaluated and medically managed over the course of 1 year with repeated echocardiograms. Costs of these interventions were analyzed and, following standard practices, a cost per quality-adjusted life-year (QALY) less than $50,000 was defined as cost-effective. RESULTS: Total costs estimates for the program ranged from $117,044 to $119,319. Cost per QALY was dependent on SHHD prevalence and the measure of effectiveness but not input costs. Cost-effectiveness (cost per QALY less than $50,000) was achieved when SHHD prevalence exceeded 11.1% for regression of SHHD, 4.7% for reversal of LVH, and 2.9% for achievement of BP control. CONCLUSIONS: In this cohort of predominantly African American patients with uncontrolled HTN, SHHD prevalence was high and screening with treatment was cost-effective across a range of assumptions. These data suggest that multidisciplinary programs such as this can be a cost-effective mechanism to mitigate the cardiovascular consequences of HTN in emergency department patients with uncontrolled BP.
Authors: James J Mahn; Elizabeth Dubey; Aaron Brody; Robert Welch; Robert Zalenski; John M Flack; Brian Ference; Phillip D Levy Journal: Acad Emerg Med Date: 2014-09 Impact factor: 3.451
Authors: Phillip Levy; Hong Ye; Scott Compton; Robert Zalenski; Timothy Byrnes; John M Flack; Robert Welch Journal: Ann Emerg Med Date: 2012-05-31 Impact factor: 5.721
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Margaret M Redfield; Richard J Rodeheffer; Steven J Jacobsen; Douglas W Mahoney; Kent R Bailey; John C Burnett Journal: Circulation Date: 2004-06-07 Impact factor: 29.690
Authors: Heather Bennett; Kelsey Laird; David Margolius; Victoria Ngo; David H Thom; Thomas Bodenheimer Journal: BMC Public Health Date: 2009-12-10 Impact factor: 3.295
Authors: Phillip D Levy; Michael J Burla; Michael J Twiner; Alexander L Marinica; James J Mahn; Brian Reed; Aaron Brody; Robert Ehrman; Allie Brodsky; Yiying Zhang; Samar A Nasser; John M Flack Journal: Am J Hypertens Date: 2020-09-10 Impact factor: 2.689
Authors: Leopold Ndemnge Aminde; Anastase Dzudie; Yacouba N Mapoure; Jacques Cabral Tantchou; J Lennert Veerman Journal: BMC Health Serv Res Date: 2021-02-12 Impact factor: 2.655
Authors: Tomasz Miazgowski; Jacek Kopec; Katarzyna Widecka; Bartosz Miazgowski; Anna Kaczmarkiewicz Journal: Arch Med Sci Date: 2019-05-17 Impact factor: 3.318